SCHEMBL30378990

SCHEMBL30378990

CC(C(=O)N1CCN(CC2CC2)c2ccccc21)N1CCN(C)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 5/20 0.46
▸ DRD4 P21917 1/20 0.44
▸ LMNA P02545 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ ATM Q13315 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26089031 1.00 SIGMAR1 (0.46) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL26088646 0.91 GAA (0.43) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL30910074 0.91 GAA (0.43) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL30379654 0.89 GAA (0.43) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL26089531 0.89 GAA (0.43) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL30378975 0.85 SMN1; SMN2 (0.48) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL26091188 0.85 SMN1; SMN2 (0.48) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL30379553 0.82 BRD4 (0.61) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL26089130 0.82 BRD4 (0.61) SIGMAR1DRD4LMNAKDM4EALDH1A1
SCHEMBL29220800 0.82 BRD4 (0.43) LMNAKDM4EALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US claimed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP claimed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 SIGMAR1 3365/4885DRD4 3728/4885LMNA 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback